Added to YB: 2026-10-13
Pitch date: 2026-10-09
CAMX.ST [bullish]
Camurus AB (publ)
-0.78%
current return
Author Info
European Hidden Gem Stocks shares deep research on under-covered European small/mid caps. Sign up for the newsletter.
Company Info
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
Market Cap
SEK 38.1B
Pitch Price
SEK 645.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
40.68
P/E
56.69
EV/Sales
15.08
Sector
Pharmaceuticals
Category
growth
Camurus AB: The Little-Known Swedish Gem Partnering With Eli Lilly on Long-Acting Medicines
CAMX.ST (overview): Camurus pairs a profitable opioid-dependence franchise with FluidCrystal, the main upside: a long-acting delivery platform licensed to Lilly for next-generation obesity compounds and expanded to amylin agonists. With Buvidal/Brixadi scaling, gross margins have remained >90% while EBITDA and net margins have risen above 30%. At 27.0x forward earnings with 27.9% forward revenue growth, the key uncertainty is which compounds FluidCrystal can support — particularly whether it applies to retatrutide — and whether partnerships produce blockbuster products.
Read full article (9 min)